JP2012531612A5 - - Google Patents

Download PDF

Info

Publication number
JP2012531612A5
JP2012531612A5 JP2012518798A JP2012518798A JP2012531612A5 JP 2012531612 A5 JP2012531612 A5 JP 2012531612A5 JP 2012518798 A JP2012518798 A JP 2012518798A JP 2012518798 A JP2012518798 A JP 2012518798A JP 2012531612 A5 JP2012531612 A5 JP 2012531612A5
Authority
JP
Japan
Prior art keywords
macro
cancer
expression
patient
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012518798A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012531612A (ja
JP5792165B2 (ja
Filing date
Publication date
Priority claimed from EP09008679A external-priority patent/EP2270510A1/en
Application filed filed Critical
Publication of JP2012531612A publication Critical patent/JP2012531612A/ja
Publication of JP2012531612A5 publication Critical patent/JP2012531612A5/ja
Application granted granted Critical
Publication of JP5792165B2 publication Critical patent/JP5792165B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012518798A 2009-07-02 2010-07-02 ヒストンマクロh2aアイソフォームに基づいて癌再発のリスクを予測する診断のための判断材料を提供する方法 Expired - Fee Related JP5792165B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09008679A EP2270510A1 (en) 2009-07-02 2009-07-02 Diagnostic method for predicting the risk of cancer recurrence based on Histone macroH2A isoforms
EP09008679.4 2009-07-02
PCT/EP2010/004008 WO2011000573A1 (en) 2009-07-02 2010-07-02 Diagnostic method for predicting the risk of cancer recurrence based on histone macroh2a isoforms

Publications (3)

Publication Number Publication Date
JP2012531612A JP2012531612A (ja) 2012-12-10
JP2012531612A5 true JP2012531612A5 (https=) 2013-08-08
JP5792165B2 JP5792165B2 (ja) 2015-10-07

Family

ID=41100520

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012518798A Expired - Fee Related JP5792165B2 (ja) 2009-07-02 2010-07-02 ヒストンマクロh2aアイソフォームに基づいて癌再発のリスクを予測する診断のための判断材料を提供する方法

Country Status (11)

Country Link
US (1) US20120171225A1 (https=)
EP (2) EP2270510A1 (https=)
JP (1) JP5792165B2 (https=)
CN (1) CN102472753B (https=)
AU (1) AU2010268389B2 (https=)
BR (1) BRPI1011925A2 (https=)
CA (1) CA2766656A1 (https=)
ES (1) ES2681687T3 (https=)
SG (1) SG177398A1 (https=)
WO (1) WO2011000573A1 (https=)
ZA (1) ZA201109381B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201115098D0 (en) * 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes containing histone variants
GB201604806D0 (en) * 2016-03-22 2016-05-04 Singapore Volition Pte Ltd Method of identifying a cancer of unknown origin
EP3508855A1 (en) * 2018-01-05 2019-07-10 Allianz Pharmascience Ltd Method for the selection of patients and kit
EP3546944A1 (en) * 2018-03-30 2019-10-02 Universite d'Aix-Marseille (AMU) Diagnosis and treatment of a cancer based on the overexpression of the adamtsl5 gene
CN108957004B (zh) * 2018-07-09 2021-10-19 东南大学 检测H3K9me2和H3K36me3表达量的试剂在制备胃癌预后评估试剂盒中的应用
CN111896740B (zh) * 2019-05-06 2025-02-11 山东大学 诊断或预测生育缺陷的试剂盒
CN119736252B (zh) * 2025-01-15 2025-06-27 首都医科大学 组蛋白变体macroH2A调控巨噬细胞功能在改善肿瘤免疫微环境中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2197915B (en) 1986-11-19 1990-11-14 Rolls Royce Plc Improvements in or relating to fluid bearings
US20020052308A1 (en) * 1999-03-12 2002-05-02 Rosen Craig A. Nucleic acids, proteins and antibodies
US20030190640A1 (en) * 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
US20030124579A1 (en) * 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20050085628A1 (en) * 2002-01-31 2005-04-21 Kinya Yoda Production of hybridoma producing antihuman cenp-a peptide monoclonal antibody and method of using the same
DE60200248T2 (de) * 2002-08-01 2005-01-27 Mtm Laboratories Ag Verfahren für Lösung-basierte Diagnose
CN100480382C (zh) * 2002-08-16 2009-04-22 抗癌公司 实时测量细胞反应
WO2004063355A2 (en) * 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
EP1640452A4 (en) * 2003-05-30 2009-12-23 Nippon Shinyaku Co Ltd OLIGOBICATENARY RNA INHIBITING BCL-2 EXPRESSION AND MEDICINAL COMPOSITION CONTAINING THE SAME
EP1682904A2 (en) * 2003-11-04 2006-07-26 Roche Diagnostics GmbH Method for distinguishing who classified aml subtypes
DE102004037860A1 (de) * 2004-08-04 2006-03-16 Friedrich-Alexander-Universität Erlangen-Nürnberg Turmormarker zur Diagnose von Karzinomen und/oder davon abstammender Metastasen
WO2006119435A2 (en) * 2005-05-04 2006-11-09 Invitrogen Corporation Identification of cancer biomarkers and phosphorylated proteins
EP1907858A4 (en) * 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
EP1948215B1 (en) * 2005-11-14 2012-01-11 Centre National De La Recherche Scientifique (Cnrs) MacroH2A non-histone domain as inhibitor of PARP-1 activity and uses thereof
EP2145021A2 (en) * 2007-05-17 2010-01-20 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
JP2008292424A (ja) * 2007-05-28 2008-12-04 Nippon Medical School 腫瘍の検出方法
EP2185728A2 (en) * 2007-09-07 2010-05-19 Université Libre de Bruxelles Methods and tools for prognosis of cancer in er- patients
US20110224313A1 (en) * 2008-06-05 2011-09-15 British Columbia Cancer Agency Branch Compositions and methods for classifying lung cancer and prognosing lung cancer survival

Similar Documents

Publication Publication Date Title
US20220334128A1 (en) Method for the enrichment of circulating tumor dna
Mocan et al. Liquid biopsies in hepatocellular carcinoma: are we winning?
Cheng et al. Diagnostic value of different phenotype circulating tumor cells in hepatocellular carcinoma
Lee et al. Aptamer-based sandwich assay and its clinical outlooks for detecting lipocalin-2 in hepatocellular carcinoma (HCC)
JP2012531612A5 (https=)
Ziol et al. ESM-1 expression in stromal cells is predictive of recurrence after radiofrequency ablation in early hepatocellular carcinoma
Ghazani et al. Molecular characterization of scant lung tumor cells using iron-oxide nanoparticles and micro-nuclear magnetic resonance
Wang et al. Emerging role of molecular diagnosis and personalized therapy for hepatocellular carcinoma
Santos et al. Liquid biopsy: The value of different bodily fluids
Block et al. The degree of readiness of selected biomarkers for the early detection of hepatocellular carcinoma: notes from a recent workshop
JP2017520763A5 (https=)
Goggins Markers of pancreatic cancer: working toward early detection
Kim et al. Role of biopsy sampling for diagnosis of early and progressed hepatocellular carcinoma
Liu et al. Identification of high independent prognostic value of nanotechnology based circulating tumor cell enumeration in first-line chemotherapy for metastatic breast cancer patients
CN102472753B (zh) 基于组蛋白macroH2A同工型预测癌症复发风险的诊断方法
Seo et al. Epidemiologic study of human epidermal growth factor receptor 2 expression in advanced/metastatic gastric cancer: an assessment of human epidermal growth factor receptor 2 status in tumor tissue samples of gastric and gastro-esophageal junction cancer
Idriss et al. Analysis of lamin B1, vimentin and anti-Ku86 as prospective biomarkers of hepatocellular carcinoma in patients with hepatitis C virus infection
US20230133776A1 (en) Methods for diagnosing cancer
JP2021019612A (ja) 治療剤に対する抵抗性の診断に使用するためのERCC1アイソフォーム3のmRNAおよび/またはタンパク質ならびにこのmRNAおよび/またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法
CN103562722A (zh) 一种区分甲状腺癌变的方法、实施该方法的试剂盒以及金属硫蛋白在区分甲状腺癌变中的用途
Wang et al. Use of cytokeratin-19 concentration to assess early recurrence and prognosis of hepatitis B virus-related hepatocellular carcinoma following radical resection in patients with a low serum alpha-fetoprotein concentration
JP2017529074A5 (https=)
JP2010216826A (ja) 新規腫瘍マーカーを用いた乳癌の検査方法
Rutkowska-Kawalec et al. Liquid biopsy-a review
Hua et al. Liquid Biopsy in the Future of Glioma Diagnosis and Treatment Occupies a Key Position